PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
for the first quarter ended March 31, 2017. The full text of the
press release issued in connection with the announcement is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
attached hereto shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Earnings Press Release dated May 4, 2017
|
About PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX)
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX) Recent Trading Information
PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX) closed its last trading session 00.00 at 45.80 with 1,522,790 shares trading hands.
